Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/10/2021 | 08:29am EST

VYNE Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 4.09 million compared to USD 3.27 million a year ago. Net loss was USD 21.29 million compared to USD 24.71 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 0.59 a year ago. For the nine months, revenue was USD 12.46 million compared to USD 16.71 million a year ago. Net loss was USD 61.76 million compared to USD 232.39 million a year ago. Basic loss per share from continuing operations was USD 1.22 compared to USD 7.98 a year ago.


© S&P Capital IQ 2021
All news about VYNE THERAPEUTICS INC.
01/19VYNE Therapeutics Completes Phase 1b Data for FMX114 for Atopic Dermatitis
MT
01/19VYNE THERAPEUTICS : Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Trea..
PU
01/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/19VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Tre..
AQ
01/19VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for th..
CI
01/14VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For..
PU
01/14VYNE THERAPEUTICS INC. Change in Directors or Principal Officers, Financial Statements..
AQ
01/14VYNE Therapeutics Inc. Announces Board Changes
CI
01/14Health Care Stocks Drop Premarket Friday
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 16,6 M - -
Net income 2021 -72,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,40x
Yield 2021 -
Capitalization 29,2 M 29,2 M -
Capi. / Sales 2021 1,76x
Capi. / Sales 2022 3,85x
Nbr of Employees 106
Free-Float -
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,54 $
Average target price 5,80 $
Spread / Average Target 964%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-46.58%29
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960